Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

CYTOKINETICS INC Director's Dealing 2017

Mar 2, 2017

30870_dirs_2017-03-02_aa2efca3-09c8-42b4-8bdf-9b446f79f1bf.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CYTOKINETICS INC (CYTK)
CIK: 0001061983
Period of Report: 2017-02-28

Reporting Person: Malik Fady Ibraham (EVP Research & Development)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2017-02-28 Common Stock A 25000 $0.0010 Acquired 25035 Direct
2017-02-28 Common Stock F 9631 $10.6 Disposed 15404 Direct
2017-02-28 Common Stock A 30000 $0.0010 Acquired 45404 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2017-02-28 Incentive Stock Option (right to buy) $10.6 A 8895 Acquired 2027-02-28 Common Stock (8895) Direct
2017-02-28 Non-Qualified Stock Option (right to buy) $10.6 A 41105 Acquired 2027-02-28 Common Stock (41105) Direct

Footnotes

F1: The restricted stock units vest in three annual installments. Vested shares will be delivered to the reporting person as follows: 40% on 02/28/2018, 40% on 02/28/2019 and 20% on 02/28/2020.

F2: When the ISO and NQ dated 02/28/2017 are combined, the total grant shall vest and become exercisable in equal monthly installments such that the option shall be 100% vested on 02/28/2021.